All In Biotech

BLA 761149 · Genentech

Enspryng

Satralizumab · Injection

NovelBreakthrough therapyOrphan

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Aug 14, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

15

9 Phase 3, 6 recruiting

FAERS reports

1,789

1,398 serious, 102 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2026.

ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients. ( 1.2 ) 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. 1.2 Thyroid Eye Disease (TED) ENSPRYNG is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.

Mechanism: The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD and TED is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ENSPRYNG · SATRALIZUMAB 120MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Satralizumab" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neuromyelitis optica spectrum disorder305
  • off label use176
  • urinary tract infection140
  • pneumonia114
  • covid-1975
  • no adverse event75
  • fatigue66
  • hypoaesthesia56
  • infection56
  • headache54
  • pain49
  • arthralgia46

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
202012
2021130
2022210
2023343
2024373
2025403
2026317

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Enspryng (Satralizumab-Mwge)

2024 spending

$45.3M

Beneficiaries

267

2,251 claims

Per beneficiary

$169,561

$16,755.31 per unit

View as table
YearSpending
2020$968,468
2021$12,327,698
2022$24,033,810
2023$33,897,861
2024$45,272,835

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.